We also detected the upregulation of PD-L1 on total cells including tumor cells from patients with a durable CBR rather than from nonresponders during anti–PD-1 therapy, and we observed a greater abundance of CD8+ T cells that were touching PD-L1+ cells in patients with a durable clinical benefit rate. This evidence concerns the gene PDCD1 and neoplasm.